Prognostic utility of the sphingolipid metabolic pathway in pancreatic ductal adenocarcinoma
Surgery · 2026-10 · 110672
DOI: 10.1016/j.surg.2026.110672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery, 2026-10. Verfasst von Ryan Johnson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, University of Cincinnati, Cincinnati, OH. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Cincinnati College of Medicine, University of Cincinnati Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Sphingolipid metabolism regulates physiologic responses through the sphingomyelin-ceramide-sphingosine-1-phosphate axis. Acid sphingomyelinase has previously been associated with improved outcomes in pancreatic cancer (pancreatic ductal adenocarcinoma). In this study, we evaluate acid sphingomyelinase in the context of additional key enzymes in the sphingolipid metabolic pathway in pancreatic ductal adenocarcinoma. METHODS: An institutional cohort of surgery-first patients (n = 23) and a cohort from the Human Protein Atlas (N = 171) were utilized to examine overall and recurrence-free survival based on key enzyme expression levels including acid sphingomyelinase, the neutral sphingomyelinases (1/2), the downstream acid ceramidase (N-acylsphingosine amidohydrolase 1), and sphingosine kinases (1/2). RESULTS: In the institutional cohort, 30% of patients had high acid sphingomyelinase expression, 74% had high neutral sphingomyelinase 1 expression, and 22% had high neutral sphingomyelinase 2 expression. There was improved overall survival associated with higher expression of neutral sphingomyelinase 1 (median overall survival, 23.0 vs 15.6 months; P = .0003), and sphingosine kinase 2 (median overall survival, not reached vs 18.9 months; P = .002), and worsened overall survival associated with high sphingosine kinase 1 expression (median overall survival, 19.6 months versus not reached). Acid sphingomyelinase expression was associated with improved recurrence-free survival (23.6 months versus 16.0 months, P = .033) and no cases of local-only recurrence (0% vs 28.6%). CONCLUSION: Sphingolipid metabolism, particularly high levels of acid sphingomyelinase expression, appears to have prognostic value in pancreatic ductal adenocarcinoma. Future work should focus on how these findings can be leveraged to improve outcomes in pancreatic cancer.
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, University of Cincinnati, Cincinnati, OH.
- Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH.
- Division of Surgical Oncology, Department of Surgery, University of Cincinnati, Cincinnati, OH. Electronic address: https://x.com/SyedAAhmad5.
- Division of Surgical Oncology, Department of Surgery, University of Cincinnati, Cincinnati, OH; Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Division of Surgical Oncology, Department of Surgery, University of Cincinnati, Cincinnati, OH. Electronic address: wilsong3@ucmail.uc.edu.
Förderung
- University of Cincinnati College of Medicine
- University of Cincinnati Cancer Institute
Zitieren
APA
Johnson, R., Satyadi, M. A., Fritson, C., Martin, C., Nikolaidis, N. M., Wang, J., Ahmad, S. A., Patel, S. H., Gulbins, E., & Wilson, G. C. (2026). Prognostic utility of the sphingolipid metabolic pathway in pancreatic ductal adenocarcinoma. Surgery, 110672. https://doi.org/10.1016/j.surg.2026.110672
Vancouver
Johnson R, Satyadi MA, Fritson C, Martin C, Nikolaidis NM, Wang J, et al. Prognostic utility of the sphingolipid metabolic pathway in pancreatic ductal adenocarcinoma. Surgery. 2026:110672. doi:10.1016/j.surg.2026.110672
BibTeX
@article{Johnson2026,
author = {Johnson, Ryan and Satyadi, Megan A and Fritson, Caden and Martin, Cora and Nikolaidis, Nikolaos M and Wang, Jiang and Ahmad, Syed A and Patel, Sameer H and Gulbins, Erich and Wilson, Gregory C},
title = {Prognostic utility of the sphingolipid metabolic pathway in pancreatic ductal adenocarcinoma},
journal = {Surgery},
year = {2026},
pages = {110672},
doi = {10.1016/j.surg.2026.110672}
}
EUVIMED